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Pelepasan natrium diklofenak dari Sediaan Transdermal Patch Tipe Matriks dengan 
kombinasi polimer etil selulosa (EC) N-20 dan polivinilpirolidon (PVP) K-30 telah diteliti. 
Pada penelitian ini sediaan transdermal patch tipe matriks  yang mengandung natrium 
diklofenak dibuat dengan kombinasi polimer etil selulosa (EC) N-20 dan polivinilpirolidon 
(PVP) K-30 pada perbandingan yang berbeda ( 9:1 (Formula I); 8:2 (Formula II); dan 7:3 
(Formula III)). Persentase (%) moisture content dihitung dari perbedaan berat relatif pada 
penimbangan akhir. Uji homogenitas permukaan patch dilakukan dengan menggunakan 
metode Scanning Electron Microscopy (SEM). Uji disolusi dengan media larutan dapar fosfat 
salin pH 7,4 ± 0.05 sebanyak 500,0 mL yang terlebih dahulu dipanaskan sampai mencapai 
temperatur percobaan 37 ± 0.5°C diaduk pada kecepatan 50 rpm. Hasil dianalisis 
menggunakan SPSS dengan metode ANOVA one way dengan tingkat kepercayaan 95% ( = 
0,05). Berdasarkan penelitian ini, penggunaan polimer kombinasi antara etil selulosa (EC) N-
20 dan polivinilpirolidon (PVP) K-30 dapat meningkatkan fluks pelepasan natrium diklofenak 
dari sediaan patch natrium diklofenak. Perbandingan 7:3 dari etil selulosa (EC) N-20 dan 
polivinilpirolidon (PVP) K-30  adalah kombinasi yang terbaik untuk sediaan patch natrium 
diklofenak karena konsistensi bentuk fisik serta nilai fluks pelepasan dan penetrasi yang 
dihasilkan lebih besar dari perbandingan lainnya. 
 






The sodium diclofenac realeased from transdermal patch of combination of ethyl cellulose 
(EC) N-20 and polyvinyl pyrollidon (PVP) K-30 was investigated. In this study, matrix-type 
of transdermal patch containing diclofenac sodium were prepared using polymeric 
combination of EC N-20  and PVP K-30 in various  ratios ( 9:1 (Formula I); 8:2 (Formula II); 
and 7:3 (Formula III)). The percentage of moisture content was calculated as a difference 
between initial and final weight with respect to final weight. The homogeneity of patch 
surface was determined using fluorescence microscope and scanning electron microscope 
(SEM). Released test using dissolution apparatus were carried out in 500 mL of phosphate 
buffer saline pH 7.4 ± 0.05 at temperature 37 ± 0.5°C with speed of swirl 50 rpm. Results 
were analyzed by statistic programmed of SPSS using one way analysis of variance with 
degree of believed 95% (α = 0,05).  It can be concluded that the combination of EC N-20 and 
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PVP K-30 at ratio 7:3 was the best choice for manufacturing transdermal patch based on 
physicochemical and the release profile. 
 




These last few years, the transdermal route 
has become one of the most successful and 
innovative focus for research in drug 
delivery. One dosage form is provided by 
transdermal patch dosage forms. Patch is a 
dosage form that aims to transport drugs 
through the skin into the blood circle [1]. 
Patch will be effective when the drug must 
obviously be able to penetrate into the skin 
barrier and reach the target [2]. Criteria 
these are typically used for selection 
include parenteral dose less than 20 
mg/day, short half-life (requiring multiple 
daily doses in current dosage form), 
acceptable skin toxicity (little or no skin 
irritation or sensitization), molecular 
weight less than 500 Daltons, log octanol-
water partition coefficient of approximately   
0–3 and solubility in mineral oil and water 
greater than 1 mg/mL3. 
Some of the drug when given in oral form, 
drugs undergoes substansial hepatic first-
pass metabolism and give side effects such 
as irritation of the stomach, so better if 
given in the patch dosage form [3]. Patch 
preferred over intravenous administration 
for not causing pain, tissue damage and 
removes the fear of patients [3].  
Sodium diclofenac is reported used for 
topical applications. The drug undergoes 
substansial hepatic first-pass metabolism 
and only 50% of administered dose reaches 
systemic circulation [4]. 
 
 
The aim of the present study is to know 
how the influence of a combination of 
ethyl cellulose polymer and 
polyvinylpyrrolidone in the ratio 9:1, 8:2 
and 7:3 in increasing the flux of diclofenac 
sodium release from matrix 100 mg/50 
cm2, added menthol as an enhancer with 
levels of 1% and polyethylene glycol 400 
as plasticizer with levels of 20%, with a 
method of making a matrix controlled, so 
as to obtain a combination of polymers 
with a precise comparison to diclofenac 





Sodium diclofenac (Aarti Drugs Limited), 
PVP K-30 (SP (Singapore) Pte Ltd), EC N-
22 (Dow Chemical Company), and 
menthol were purchased from PT 
Bratachem. All ingredients of these were 
pharmaceutical grade, alcohol 96% was 
analytical grade.   
 
Preparation 
Dosage sodium diclofenac patch matrix 
type controlled by the ratio of different 
polymers made planned to produce an 
average weight of 0.500 grams with a 
diameter of 3 cm, surface area 7.065 cm2 
(table 1).PVP K-30 and EC N-20, 
respectively - were dissolved in ethanol 
96%. Solution of PVP K-30 included in the 
solution of N-20 EC, stirring until evenly 
mixed. Previously menthol solution was 
made by dissolving 0.050 grams of 
menthol in ethanol 96% to 100 mL. 
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Table 1. Formula of the sodium diclofenac patch base 
Material  
Concentration  (mg/7.065 cm2) 
Formula 1 Formula 2 Formula 3 Formula 4 








EC N-20 342.78 304.70 266.61 228.52 
PVP K-30 38.09 76.17 114.26 152.35 
Polyetylenglikol 400 100 100 100 100 





Figure 1.   The results of organoleptics evaluation of the sodium diclofenac patch, A=formula 9:1; B= formula 
8:2 and C= formula 7:3 
 
For each - each formula, 1.0 mL of 
menthol solution was poured into the 
sodium diclofenac, stirred until dissolved. 
Mixture of diclofenac sodium and menthol 
added to the mixture of PVP K-30 and EC 
N-20. Stirred carefully until all the 
ingredients mixed. Polyethylene glycol 400 
and the remaining 96% ethanol solutions 
were added gradually while continue to be 
stirring until homogeneous. After a 
homogeneous preparation was poured into 
a mold and dried at room temperature for 
24 hours. 
 
Evaluation of patches Moisture content 
The prepared flms were weighted 
individually and kept in a dessicator 
containing silica at room temperature for 
24 hours. The films were weighed again 
and again until they showed a constant 
weight. The percent moisture content was 
calculated using the following formula: 
Percent moisture content = (initial weight-
final weight/final weight) x100. 
 
 
Homogeneity of the patch surface  
Homogeneity of patch surface was 
analyzed using a fluorescence microscope 
and a scanning electron microscope (SEM). 
 
In Vitro Release Studies 
The in vitro release of the patches was 
performed using USP dissolution apparatus 
5-paddle over disk with completely cell 
diffusion.  
The patches (in cell diffusion) were placed 
respective in the dissolution chamber.  All 
in vitro released study were performed at 
50 rpm, with each medium of dissolution 
(phosphate buffer saline pH 7.4 ± 0.05 at 
temperature 37 ± 0.5°C) was 500 mL. The 
samples withdrawn at different time 
intervals were analyzed for drug content 
using spectrophotometer Double Beam 
UV-VIS Recording UV 160 A (Shimadzu). 
All of the results were analyzed by statistic 
programmed of SPSS using one way 
analysis of variance with degree of 
believed 95% (α = 0,05). 
A B C 
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Figure 2.  Histogram of the moisture content patch sodium diclofenac. Each column   represents the mean ± 
SD (n=3). 
 
A1 (9:1)                  B1 (Kontrol 9:1) 
 
Figure 3.  The results of Fluorescence microscope images of diclofenac sodium patch using electron 
microscope Olympus DX 41 Nokuler Three types of TF with 100x magnification. A: patch type 
polymer matrix with a ratio of ethyl cellulose (EC) N-20-polyvinylpyrrolidone (PVP) K-30 in a row 
is: A1 = 9:1; A2 = 8:2; A3 = 7:3; control patch type polymer matrix with a ratio of ethyl cellulose 
(EC) N-20-polyvinylpyrrolidone (PVP) K-30 in a row are: B1 = 9:1; B2 = 8:2; B3 = 7:3 












 Formula 1 Formula 2  Formula 3 
Moisture Content (%) 
A2 (8:2) B2 (Kontrol 8:2) 
A3 (7:3) B3 (Kontrol 7:3) 
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Figure 4.  The results of electron microscope images of diclofenac sodium patch using Scanning Electron 
Microscope with (SEM) with 500x magnification. A: patch type polymer matrix with a ratio of ethyl 
cellulose (EC) N-20-polyvinylpyrrolidone (PVP) K-30 in a row is: A1 = 9:1; A2 = 8:2; A3 = 7:3 
 
RESULT AND DISCUSSION 
The results of organoleptics evaluation 
showed that the composition of patch 
formulation using combination polymer EC 
N-20 and PVP K-30 at ratio 9:1 and 8:2 
more rigid and not easy to breaking 
compared with that of ratio 7:3 
(figure1).Physicochemical parameter of the 
prepared formulation were evaluated in this 
study. The percentage moisture content of 
the formulation was determined (figure 2). 
The result of moisture content studies 
showed that the %value  SD of moisture 
content from 3 replication of formula 1 was 
8.67 ± 1.33; formula 2 12.30 ± 3.42 and 
formula 3 was 13.30 ± 1.65. The results 
showed with an increasing percentage of 
hydrophilic polymers, PVP K-30, in the 
formulation, moisture content increased. 
Fluorescence microscope and a Scanning 
electron microscope (SEM) study showed 
the surface of the sodium diclofenac matrix 
(figure 3 dan 4). Observations using 
electron microscopy at 100x magnification 
showing the addition of polymers PVP-
K30 diclofenac sodium patch causes the 
surface to be uneven, and this is because 
the formation of pores on the surface of the 
matrix that will assist the release of 
diclofenac sodium. To clarify the results 
observed with electron microscope 
photographs, images can be compared with 
surface patches using a scanning Electron 
Microscope (SEM) with 500x 
magnification. Results from SEM images 
show the formation of pores on the surface 
of diclofenac sodium patch. The greater the 
levels of polyvinylpyrrolidone (PVP) K-30, 
the pores formed are larger and spread out 
evenly across the surface of the patch. 
The results of in vitro drug release 
are presented in figure 5, showed the 
released process of sodium diclofenac from 
patch base. The cumulative amount of the 
drug released from patch base was plotted 
as a function root of time and a linear 
regression analysis was used to determine 
the flux of sodium diclofenac.  
Figure 6 shows the flux of sodium 
diclofenac from the patch base. Based on 
the in vitro released study, the flux of 
diclofenac from patch base were 37.482 ± 
15.529 μg/cm²/minute½; 34.587 ± 4.027 
μg/cm²/minute½; and 43.540 ± 2.555 
μg/cm²/minute½ respectively for Formula I, 
Formula II and Formula III. The result of 
statistic using ANOVA one way showed 
that Fcalculated (0.712) > Ftable (5.14). It 
means that there was no significant 
difference in increased concentration of 
PVP K-30 in formulation of sodium 
diclofenac patch. But the highest flux of 
piroxicam was 43.540±2.555 
μg/cm²/minute½ with the highest 
concentration of PVP K-30 and the 
smallest concentration of the EC N-22 
between all of the formula. PVP K-30 in 
matrix would form pores for released 
sodium diclofenac. This phenomena was 
similar with result of the preview research 
        A1 (9:1)              A2 (8:2)                            A3 (7:3) 
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that said with increasing the hydrophilic 
polymer the formed of pores in the matrix 
increased, so that the released of the drug 
increased [5]. 
Based on this study, the using of polymer 
combination between PVP K-30 and EC N-
22 could increase flux released of sodium 
diclofenac from patch base. The ratio of 
7:3 for PVP K-30 and EC N-30 at Formula 
III was the optimal composition for base of 
patch sodium diclofenac type matrix with 




The polymeric combination PVP K-30 and 
EC N-22 at ratio 7:3 (Formula III) was the 
best choice for manufacturing transdermal 
patch base of sodium diclofenac among the 
formulations studies with the highest value 



























































Figure 5.  Profil of Sodium diclofenac released from patch bases to phosphate buffer saline solution pH 










































Figure 6. Histogram of the flux of Sodium diclofenac released from patch bases to phosphate buffer saline 
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